Document is current
Any future updates will be listed below
-
Authors
Pan, Hui
Tian, Ai-Ling
Chen, Hui https://orcid.org/0000-0002-1260-8617
Xia, Yifan
Sauvat, Allan
Moriceau, Stephanie https://orcid.org/0000-0002-1413-9359
Lambertucci, Flavia
Motiño, Omar
Zhao, Liwei
Liu, Peng https://orcid.org/0000-0002-1682-9222
Mao, Misha
Li, Sijing
Zhang, Shuai
Joseph, Adrien
Durand, Sylvère
Aprahamian, Fanny
Luo, Zeyu
Ou, Yang
Shen, Zhe
Xue, Enfu
Pan, Yuhong
Carbonnier, Vincent https://orcid.org/0000-0002-2795-5013
Stoll, Gautier
Forveille, Sabrina
Leduc, Marion
Cerrato, Giulia
Cerone, Alexandra
Maiuri, Maria Chiara
Castinetti, Frederic
Brue, Thierry https://orcid.org/0000-0001-8482-6691
Wang, Hongsheng https://orcid.org/0000-0001-5725-5053
Ma, Yuting https://orcid.org/0000-0001-6267-1852
Martins, Isabelle https://orcid.org/0000-0003-0885-613X
Kepp, Oliver https://orcid.org/0000-0002-6081-9558
Kroemer, Guido https://orcid.org/0000-0002-9334-4405
- License Information
-
More Information
Article History
Received: 30 November 2023
Accepted: 24 October 2024
First Online: 22 November 2024
Competing interests
: O.K. is a scientific co-founder of Samsara Therapeutics. I.M. consults for Osasuna Therapeutics. G.K. has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sutro, Tollys and Vascage. G.K. is on the Board of Directors of the Bristol Myers Squibb Foundation France. G.K. is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio; is in the scientific advisory boards of Hevolution, Institut Servier, Longevity Vision Funds and Rejuveron Life Sciences; and is the inventor of patents covering therapeutic targeting of ageing, cancer, cystic fibrosis and metabolic disorders. Among these patents, one, ‘Methods for weight reduction’ (US11905330B1), is relevant to this study. G.K.’s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. G.K.’s wife, Laurence Zitvogel, has held research contracts with GSK, Incyte, Lytix, Kaleido, Innovate Pharma, Daiichi Sankyo, Pilege, Merus, Transgene, 9m, Tusk and Roche, was on the on the Board of Directors of Transgene, is a co-founder of everImmune and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. The funders had no role in the design of the study, in the writing of the manuscript or in the decision to publish the results. The other authors declare no competing interests.
